Introduction {#s1}
============

Studies have consistently demonstrated that a higher mean blood pressure (BP) is associated with a higher risk of all-cause mortality and cardiovascular morbidity and mortality \[[@R01], [@R02]\]. However, BP does not remain steady but instead fluctuates continually within a 24-h period; this occurs from day to day and from month to month \[[@R03], [@R04]\]. This BP variability (BPV) has also been shown to be a risk factor for future cardiovascular events and mortality \[[@R05]\]. Therefore, it is of great clinical interest to determine whether BPV can serve as a target of BP-lowering therapy and to identify effective antihypertensive medications that can effectively reduce BPV. However, several studies have shown that various antihypertensive drug classes differentially influence BPV \[[@R08], [@R09]\].

A large amount of evidence indicates that angiotensin II receptor blockers (ARBs) reduce cardiovascular events in patients with hypertension \[[@R10]\]. Azilsartan, which is a recently approved ARB, reportedly has greater antihypertensive effects than other ARBs \[[@R11], [@R12]\]. In addition, several studies have shown that azilsartan has pleiotropic effects such as improvement in cardiometabolic parameters \[[@R13]\]. Thus, azilsartan is a promising ARB for primary and secondary prevention of cardiovascular disease.

The purpose of this prospective study was to evaluate the effect of azilsartan after switching from another ARB on day-to-day BPV derived from home BP monitoring.

Materials and Methods {#s2}
=====================

Patient population {#s2a}
------------------

Participants were enrolled at six affiliated hospitals or clinics of Okayama University in Japan from July 2013 to June 2015. The study was approved by the ethics committees of all hospitals and clinics. All participants provided written informed consent before enrollment. This study was conducted according to the principles expressed in the Declaration of Helsinki. The study is registered in the UMIN Clinical Trials Registry (UMIN000012586).

Eligible patients were adults (\> 30 and \< 85 years old) who were undergoing treatment with an ARB (excluding azilsartan) but did not achieve the target BP according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2009 (JSH2009) \[[@R17]\]. Patients with the following conditions were excluded: secondary hypertension, grade III hypertension according to the JSH 2009 guideline \[[@R17]\], congestive heart failure, severe valvular heart disease, myocardial infarction or cerebellar infarction within 6 months, chronic atrial filtration, malignant arrhythmia, renal insufficiency (serum creatinine concentration ≥ 2 mg/dL), severe liver disease, chronic inflammatory disease, malignant disease (lifetime prognosis \< 6 months), and treatment with a renin-angiotensin system inhibitor other than an ARB.

Study protocol {#s2b}
--------------

The AziLsartan treatMent as a swItch strateGy for improvement of uncontrolled Hypertension and blood pressure variabiliTY (ALMIGHTY) was a 24-week, prospective, multicenter, open-label study with a single treatment arm ([Fig. 1](#F1){ref-type="fig"}). Eligible subjects were assigned to receive azilsartan at 20 mg, and after 12 weeks, dose titration was permitted up to 40 mg if BP lowering was insufficient according to the JSH 2009 guideline \[[@R17]\]. Treatment was continued for 24 weeks. Other drugs that could potentially interfere with the efficacy of the study medications were not allowed. All patients were reviewed for general health and compliance with medication, which was assessed by tablet counts and BP checks at each office visit.

![Study protocol. ARB: angiotensin II receptor blocker; BP: blood pressure; BPV: blood pressure variability.](jocmr-09-618-g001){#F1}

The primary outcome was the change in the day-to-day home morning BPV. The day-to-day home BPV was defined as the standard deviation (SD) and the coefficient of variation (CV) of the SD of BP on 5 consecutive days (SD and CV of 5 day-to-day readings) \[[@R18], [@R19]\]. The CV was defined as the within-individual SD divided by the mean BP. To avoid a multiplicity issue, we prioritized the SD. The secondary outcome was the change in arterial stiffness, which was measured by the cardio-ankle vascular index (CAVI).

Our calculations revealed that a sample of 210 patients would provide a power of 95% and type I error of 5% to detect a ≥ 1-mm Hg decrease in the primary outcome. We assumed that the SD of the day-to-day home BPV would decrease from 8 mm Hg (SD, 4 mm Hg) to 7 mm Hg (SD, 4 mm Hg) \[[@R20]\].

Measurement of clinic and home BP {#s2c}
---------------------------------

Office BP was measured in a sitting position three times at 1-min intervals using a validated oscillometric device after an initial 5 min of seated rest. Home BP was measured in a sitting position three times each morning and three times each evening for 5 consecutive days before the office visit (total of three visits) using a validated oscillometric device. The subjects were instructed to rest for 5 min before the first reading and rest for a 15-s interval between readings. Morning BP was measured within 1 h after waking, after urination, and before breakfast. Evening BP was measured just before going to bed and ≥ 60 min after taking a bath according to Japanese home BP guidelines \[[@R21]\].

Arterial stiffness measurement {#s2d}
------------------------------

To assess arterial stiffness, the CAVI was measured automatically using a VaSera (Fukuda Denshi, Tokyo, Japan) from the BP and pulse wave velocity (PWV) measurements while monitoring the electrocardiogram and heart sounds \[[@R22]\]. The PWV was calculated by dividing the distance from the aortic valve to the ankle artery by the sum of the time between the aortic valve closing sound and the notch of the brachial pulse wave and the time between the rise of the brachial pulse wave and the ankle pulse wave. The CAVI was determined using the following equation: CAVI = a((2ρ/ΔP) × ln(Ps/Pd) × PWV^2^) + b, where Ps and Pd are the systolic and diastolic BP, respectively; PWV is the PWV between the heart and ankle; ΔP is Ps - Pd; ρ is the blood density; and a and b are constants. The average of right and left CAVI was used for analysis.

Statistical analysis {#s2e}
--------------------

Continuous variables are presented as mean ± SD, and categorical variables are presented as absolute value and proportion (%). Variables at 3 and 6 months were compared with baseline data using a paired *t*-test. The threshold level for statistical significance was established at P \< 0.05 (two-sided test). Statistical analysis was performed using SPSS 24.0 for Windows (IBM Corp., Armonk, NY, USA).

Results {#s3}
=======

Characteristics of the study participants {#s3a}
-----------------------------------------

During the entry period, 36 patients were enrolled in this study. Of them, 28 patients completed the study (eight patients were lost to follow-up). [Table 1](#T1){ref-type="table"} shows the baseline characteristics of all subjects. Their mean age was 69 years, and 46% were men. The proportion of patients with diabetes mellitus and dyskinesia were 17% and 43%, respectively. The ARBs taken by the participants before starting this study were candesartan 4 mg (67%), losartan 50 mg (4%), olmesartan 20 mg (21%), valsartan 80 mg (4%), and telmisartan 40 mg (4%). All patients received an ARB with or without one other drug.

###### Baseline Characteristics

  ------------------------------------------------- ------------
  Age, years                                        69 ± 11
  Men, n (%)                                        13 (46%)
  Body mass index (kg/m^2^)                         24.2 ± 3.6
  Diabetes mellitus, n (%)                          3 (17%)
  Dyslipidemia, n (%)                               12 (43%)
  Chronic kidney disease, n (%)                     5 (18%)
  History of coronary artery disease, n (%)         2 (7%)
  History of cerebrovascular disease, n (%)         2 (7%)
  Current smoker, n (%)                             1 (4%)
  Angiotensin receptor blockers before enrollment   
    Candesartan 4 mg, n (%)                         19 (67%)
    Losartan 50 mg, n (%)                           1 (4%)
    Olmesartan 20 mg, n (%)                         6 (21%)
    Valsartan 80 mg, n (%)                          1 (4%)
    Telmisartan 40 mg, n (%)                        1 (4%)
  Concomitant medications                           
    Calcium channel blockers, n (%)                 11 (39%)
    Diuretics, n (%)                                2 (7%)
    Beta blockers, n (%)                            5 (18%)
  ------------------------------------------------- ------------

Data are expressed as mean ± standard deviation or number (%).

Effects of azilsartan on day-to-day home BPV {#s3b}
--------------------------------------------

The office and home BPs did not change significantly between baseline and follow-up ([Table 2](#T2){ref-type="table"}). [Table 3](#T3){ref-type="table"} shows the day-to-day home BPV. For the morning BP, the mean of the SD of the systolic BPV was significantly lower at 12 and 24 weeks than at baseline (P = 0.04 and P = 0.04, respectively). The mean of the CV of the systolic BPV was also significantly at 12 and 24 weeks lower than baseline (P = 0.04 and P = 0.04). The mean of the SD of the diastolic BPV was significantly lower at 12 and 24 weeks than at baseline (P = 0.04 and P = 0.03, respectively). The mean of the CV of the diastolic BPV was significantly lower than baseline only at 12 weeks (P = 0.04). For the evening BP, however, no significant changes were observed in the systolic and diastolic BPVs.

###### Mean Office and Home Blood Pressures

                             Baseline       12 weeks       24 weeks
  -------------------------- -------------- -------------- --------------
  Office                                                   
    Systolic BP (mm Hg)      140.3 ± 15.7   139.3 ± 19.4   136.8 ± 16.0
    Diastolic BP (mm Hg)     80.3 ± 13.7    79.8 ± 12.3    76.8 ± 11.2
    Heart rate (beats/min)   77.3 ± 12.6    76.1 ± 12.2    74.6 ± 10.7
  Home (morning)                                           
    Systolic BP (mm Hg)      136.9 ± 13.1   136.2 ± 12.0   133.3 ± 10.0
    Diastolic BP (mm Hg)     79.9 ± 10.2    79.2 ± 9.9     79.6 ± 9.6
    HR (beats/min)           67.4 ± 7.6     68.2 ± 8.6     67.1 ± 7.1
  Home (evening)                                           
    Systolic BP (mm Hg)      134.2 ± 16.6   130.1 ± 14.3   130.2 ± 10.8
    Diastolic BP (mm Hg)     76.3 ± 11.8    75.4 ± 10.3    73.2 ± 9.0
    Heat rate (beats/min)    67.5 ± 6.2     69.5 ± 6.2     64.2 ± 6.7

Data are expressed as mean ± standard deviation. BP: blood pressure.

###### Day-to-Day Home Blood Pressure Variability

                   Baseline    12 weeks      24 weeks
  ---------------- ----------- ------------- -------------
  Morning                                    
    Systolic BP                              
      SD (mm Hg)   7.4 ± 3.6   6.3 ± 3.3\*   6.1 ± 3.2\*
      CV (%)       5.4 ± 2.7   4.6 ± 2.4\*   4.6 ± 2.3\*
    Diastolic BP                             
      SD (mm Hg)   4.8 ± 2.8   3.9 ± 1.7\*   3.6 ± 1.9\*
      CV (%)       5.9 ± 3.5   4.8 ± 2.3\*   4.5 ± 2.4
  Evening                                    
    Systolic BP                              
      SD (mm Hg)   6.9 ± 3.7   6.2 ± 3.1     6.2 ± 3.2
      CV (%)       5.1 ± 2.5   4.8 ± 2.2     4.8 ± 2.4
    Diastolic BP                             
      SD (mm Hg)   4.2 ± 2.4   4.0 ± 2.0     4.1 ± 2.2
      CV (%)       5.5 ± 2.6   5.3 ± 2.6     5.6 ± 3.0

Data are expressed as mean ± SD. BP: blood pressure; SD: standard deviation; CV: coefficient of variation. \*P \< 0.05 vs. baseline.

Change in arterial stiffness {#s3c}
----------------------------

Of the patients who completed this study, 18 patients underwent CAVI measurement at baseline and at follow-up. The CAVI was significantly decreased from 8.3 ± 0.8 to 8.1 ± 0.8 (P = 0.03).

Discussion {#s4}
==========

To the best of our knowledge, this is the first study to evaluate the effect of azilsartan after switching from another ARB on the day-to-day variability in home BP. Azilsartan treatment for 24 weeks significantly reduced the day-to-day BPV in the morning. Azilsartan also decreased the arterial stiffness as determined by the CAVI, suggesting the mechanism underlying the reduction in home BPV.

Several previous studies have shown the effect of antihypertensive therapy on day-to-day BPV. However, the results were controversial. Ishikura et al \[[@R23]\] reported that use of an ARB without taking a calcium channel blocker increased the day-to-day BPV. However, Matsui et al \[[@R20]\] reported that the combined use of an ARB with a calcium channel blocker reduced the day-to-day BPV. Another group showed that alpha-adrenergic inhibitors also reduce day-to-day BPV \[[@R24]\]. A recent large prospective study of home BP showed that the effects of antihypertensive drug therapy on BPV did not differ among calcium channel blockers, angiotensin converting enzyme inhibitors, and ARBs \[[@R25]\]. However, azilsartan is a recently approved ARB. Experimental studies have demonstrated that azilsartan has an antioxidative effect \[[@R13]\], improves the metabolic profile \[[@R14], [@R15]\], and restores endothelial function \[[@R16]\]. In addition, Ishiguro et al \[[@R26]\] reported the possibility that azilsartan contributes to regression of arteriosclerosis in rats. In fact, our data showed a decrease in arterial stiffness by azilsartan. Thus, improvements in metabolic factors may reduce activation of the sympathetic nervous system and lead to amelioration of baroreflex sensitivity. Taken together, these findings indicate that the decrease in peripheral resistance induced by azilsartan may contribute to a reduction in the day-to-day BPV.

The Ohasama study \[[@R06]\] and the Finn-Home study \[[@R27]\] showed that an increased day-to-day BPV is a predictor of cardiovascular events independent of the mean BP. Several cross-sectional studies have shown that day-to-day BPV is associated with target organ damage such as left ventricular hypertrophy \[[@R28]\] and proteinuria \[[@R24]\]. One study demonstrated that day-to-day BPV was more closely associated with improvement in left ventricular hypertrophy and arterial stiffness as represented by the PWV than were ambulatory BPV and visit-to-visit BPV \[[@R29]\]. However, a recent large prospective interventional study demonstrated that day-to-day BPV had no impact on prognosis in patients with mild to moderate hypertension \[[@R25]\]. Further studies to evaluate the clinical benefit of day-to-day BVP for risk assessment of future cardiovascular events are warranted.

Limitations {#s4a}
-----------

This study has several limitations. First, it was an open-labeled, single-arm trial and may thus have potentially biased results. Second, the planned sample size was not achieved, and the study was underpowered. However, we found a significant change in the primary outcome even in this sample number, which may mitigate the influence of the lower-powered statistical test on the conclusion of the study. Third, the 5-day home BP measurement period may have been too short to accurately estimate the day-to-day home BPV, and this may have affected the results. Fourth, this study evaluated the SD and CV as parameters of the day-to-day home BPV. However, recent studies suggest the use of other parameters such as the average real variability \[[@R30]\] or variability independent of the mean \[[@R03]\] to avoid the influence of the mean BP. Future studies should determine the optimal number of home BP measurements and identify the optimal parameter of home BPV needed to obtain reliable and valid estimates of the day-to-day home BPV.

Conclusions {#s4b}
-----------

This study has demonstrated that 24 weeks of azilsartan treatment after switching from another ARB significantly reduced the day-to-day BPV in the morning. Azilsartan also decreased the arterial stiffness, suggesting the mechanism underlying the reduction in home BPV. However, our study was unable to show whether the reduction in the home BPV by azilsartan can lead directly to better outcomes. Further studies are needed to determine this.
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